论文部分内容阅读
目的探讨拉米夫定短期内阻断重度慢性乙型肝炎疾病进展的疗效。方法 40例慢性乙型肝炎有向重型肝炎发展倾向的患者随机分成2组,治疗组和对照组各20例患者。2组均采用综合性护肝治疗,治疗组加用拉米夫定,100 mg,每天1次,口服,疗程8周。观察2组患者临床症状、血清生化指标、重型肝炎的发生率、存活率和病毒学指标等。结果 (1)治疗组重型肝炎的发生率低于对照组,差异有显著性意义(x~2=5.01,P<0.05);(2)治疗组患者的存活率高于对照组,差异有统计学意义(x~2=4.51,P<0.05);(3)HBVDNA 的下降率明显高于对照组,差异有统计学意义(t=6.57,P<0.05)。结论拉米夫定能在短期内阻断重度慢性乙型肝炎进展,提高存活率,有效阻止 HBV 的复制。
Objective To investigate the efficacy of lamivudine in blocking the progression of severe chronic hepatitis B in a short term. Methods Forty patients with chronic hepatitis B who had the tendency to develop severe hepatitis were randomly divided into two groups, 20 patients in the treatment group and the control group. 2 groups were treated with comprehensive liver protection, the treatment group plus lamivudine, 100 mg, 1 day, oral, treatment for 8 weeks. Clinical symptoms, serum biochemical indexes, the incidence of severe hepatitis, survival rate and virological indicators were observed in 2 groups of patients. Results (1) The incidence of severe hepatitis in the treatment group was lower than that in the control group, with significant difference (x ~ 2 = 5.01, P <0.05); (2) The survival rate of the treatment group was higher than that of the control group (X ~ 2 = 4.51, P <0.05); (3) The rate of decline of HBVDNA was significantly higher than that of the control group (t = 6.57, P <0.05). Conclusions Lamivudine can block the progress of severe chronic hepatitis B in a short term, improve the survival rate and effectively prevent the replication of HBV.